digital health companies glp-1 management The future of drugs in healthcare: Vital's role in enhancing metabolic treatment programs Beyond the Hype: Where and

Peer review Peer review information Nature Chemical Biology thanks Alejandra Tomas and the other, anonymous reviewers for their contribution to the peer review of this work

& Yin, M

The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)

[26] [27] LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake

(2) Studies in acromegaly patients (natural GH excess) showed Hexarelin still improved left ventricular function via CD36proving GH-independent cardiac effects in humans

Kweh FA, Miller JL, Sulsona CR, Wasserfall C, Atkinson M, Shuster JJ, et al